norditropin simplexx 5 mg/1,5 ml injektionsvätska, lösning i cylinderampull
orifarm ab - somatropin - injektionsvätska, lösning i cylinderampull - 5 mg/1,5 ml - somatropin 3,3 mg aktiv substans; mannitol hjälpämne
norditropin simplexx 10 mg/1,5 ml injektionsvätska, lösning i cylinderampull
orifarm ab - somatropin - injektionsvätska, lösning i cylinderampull - 10 mg/1,5 ml - somatropin 6,7 mg aktiv substans; mannitol hjälpämne
testavan 20 mg/g transdermal gel
the simple pharma company limited - testosteron - transdermal gel - 20 mg/g - testosteron 20 mg aktiv substans; propylenglykol hjälpämne; etanol, vattenfri hjälpämne
imlygic
amgen europe b.v. - talimogen laherparepvec - melanom - antineoplastiska medel - imlygic är indicerat för behandling av vuxna med icke-resektabelt melanom som är regionalt eller avlägset metastaserad (stage iiib, iiic och ivm1a) med inga ben, hjärnan, lung- eller andra visceral sjukdom.
cibinqo
pfizer europe ma eeig - abrocitinib - dermatit, atopisk - andra dermatologiska preparat - cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.
olumiant
eli lilly nederland b.v. - baricitinib - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisbaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). olumiant kan användas som monoterapi eller i kombination med metotrexat. atopic dermatitisolumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy. alopecia areatabaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5. juvenile idiopathic arthritisbaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic dmards:- polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [rf+] or negative [rf-], extended oligoarticular),- enthesitis related arthritis, and- juvenile psoriatic arthritis. baricitinib may be used as monotherapy or in combination with methotrexate.
zovirax 200 mg tablett
glaxosmithkline ab - aciklovir - tablett - 200 mg - laktosmonohydrat hjälpämne; aciklovir 200 mg aktiv substans - aciklovir
aciclovir sun 200 mg tablett
sun pharmaceutical industries europe b.v. - aciklovir - tablett - 200 mg - aciklovir 200 mg aktiv substans - aciklovir
aciclovir sandoz 200 mg tablett
sandoz a/s - aciklovir - tablett - 200 mg - aciklovir 200 mg aktiv substans; laktosmonohydrat hjälpämne - aciklovir
zovirax 40 mg/ml oral suspension
glaxosmithkline ab - aciklovir - oral suspension - 40 mg/ml - glycerol hjälpämne; metylparahydroxibensoat hjälpämne; sorbitol hjälpämne; propylparahydroxibensoat hjälpämne; aciklovir 40 mg aktiv substans - aciklovir